Inadvertent relaxation of the ductus arteriosus by pharmacologic agents that are commonly used in the neonatal period.

Reese J, Veldman A, Shah L, Vucovich M, Cotton RB
Semin Perinatol. 2010 34 (3): 222-30

PMID: 20494739 · PMCID: PMC2920501 · DOI:10.1053/j.semperi.2010.02.007

Premature birth and disruption of the normal maturation process leave the immature ductus arteriosus unable to respond to postnatal cues for closure. Strategies that advocate conservative management of the patent ductus arteriosus (PDA) in premature infants are dependent on identification of the symptomatic PDA and understanding the risk factors that predispose to PDA. Exposure of premature infants to unintended vasodilatory stimuli may be one of the risk factors for PDA that is under recognized. In this article, we summarize the clinical factors that are associated with PDA and review commonly used neonatal drugs for their vasodilatory properties. Data demonstrating relaxation of the ductus arteriosus by gentamicin and other aminoglycoside antibiotics, by cimetidine and other H2 receptor antagonists, and by heparin are provided as examples of neonatal therapies that have unanticipated effects that may promote PDA.

MeSH Terms (16)

Animals Cimetidine Ductus Arteriosus Ductus Arteriosus, Patent Gentamicins Heparin Histamine H2 Antagonists Humans Infant, Newborn Infant, Premature Infant, Premature, Diseases Nitric Oxide Prostaglandins Risk Factors Vasodilation Vasodilator Agents

Connections (1)

This publication is referenced by other Labnodes entities:

Links